



Dear Infection Preventionist,

The Division of Healthcare Quality Promotion (DHQP) at the Centers for Disease Control and Prevention (CDC) has been analyzing microbiology laboratory practice data from the National Healthcare Safety Network (NHSN) Annual Facility Survey. We are contacting participating facilities to verify specific survey responses. You will likely need to contact your microbiology laboratory in order to answer these questions.

In the 2008 NHSN annual survey (completed in 2009), your facility was listed as using Vitek for primary antimicrobial susceptibility testing for *Klebsiella pneumoniae*. Although still FDA approved for use in antimicrobial susceptibility testing, the original Vitek platform (also known as Vitek Legacy) is being phased-out by its manufacturer and has not been updated since 2005. Please indicate whether the primary method for antimicrobial susceptibility testing for *Klebsiella pneumoniae* at your facility in 2008 was Vitek (a.k.a. Vitek Legacy) and not Vitek 2 or another method.

1. What is your facility's NHSN orgID? _____
2. What is the name of your facility? _____
3. What was the primary method of antimicrobial susceptibility testing used by your facility for *Klebsiella pneumoniae* in 2008 (circle one)?
 - a. Kirby-Bauer disk diffusion
 - b. Vitek (Legacy)
 - c. Vitek 2
 - d. Sceptor
 - e. BD Phoenix
 - f. Sensititre
 - g. Microscan walkaway rapid
 - h. Microscan walkaway conventional
 - i. Microscan auto or touchscan
 - j. Other micro-broth dilution method
 - k. Agar dilution method
 - l. Pasco
 - m. Micromedia
 - n. E-test
 - o. Other
(list: _____)
4. What is the **current** primary method of antimicrobial susceptibility testing used by your facility for *Klebsiella pneumoniae* (circle one)?
 - a. Kirby-Bauer disk diffusion
 - b. Vitek (Legacy)
 - c. Vitek 2
 - d. Sceptor
 - e. BD Phoenix
 - f. Sensititre
 - g. Microscan walkaway rapid
 - h. Microscan walkaway conventional
 - i. Microscan auto or touchscan
 - j. Other micro-broth dilution method
 - k. Agar dilution method
 - l. Pasco
 - m. Micromedia
 - n. E-test
 - o. Other
(list: _____)
5. If your facility used Vitek (Legacy) in 2008 for primary susceptibility testing of *Klebsiella pneumoniae* (1b above) and is now using a different method (2 above), when did this change take place?
_____ (MM/YYYY)

The Clinical and Laboratory Standards Institute (CLSI) publishes their antimicrobial susceptibility standards annually in their M100 document. In the 2008 NHSN annual survey (completed in 2009), your facility was listed as using an M100 document version S15 or lower. Please answer the following questions to verify this information

6. What version of the CLSI M100 document was used by your microbiology laboratory **in 2008** (circle one)?
- | | |
|----------------------|-------------|
| a) M100-S10 or lower | f) M100-S15 |
| b) M100-S11 | g) M100-S16 |
| c) M100-S12 | h) M100-S17 |
| d) M100-S13 | i) M100-S18 |
| e) M100-S14 | |
7. What version of the CLSI M100 document is **currently** being used by your microbiology laboratory (circle one)?
- | | | |
|----------------------|-------------|-------------|
| a. M100-S10 or lower | e. M100-S14 | i. M100-S18 |
| b. M100-S11 | f. M100-S15 | j. M100-S19 |
| c. M100-S12 | g. M100-S16 | k. M100-S20 |
| d. M100-S13 | h. M100-S17 | l. M100-S21 |

To submit these responses, please follow the SurveyMonkey link in the original e-mail, or scan and e-mail this back to PTosh@CDC.gov, or mail to:

Pritish Tosh, MD
CDC
1600 Clifton Road, MS-A-24
Atlanta, GA 30333